202 related articles for article (PubMed ID: 20586711)
21. Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer.
Laurie SA; Goss GD
J Clin Oncol; 2013 Mar; 31(8):1061-9. PubMed ID: 23401452
[TBL] [Abstract][Full Text] [Related]
22. The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
Sequist LV
Clin Adv Hematol Oncol; 2015 Mar; 13(3):147-9. PubMed ID: 26352419
[No Abstract] [Full Text] [Related]
23. A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer.
Govindan R
Clin Lung Cancer; 2010 Jan; 11(1):8-12. PubMed ID: 20085861
[TBL] [Abstract][Full Text] [Related]
24. [I. What is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?].
Urata Y; Satouchi M
Gan To Kagaku Ryoho; 2015 Aug; 42(8):931-4. PubMed ID: 26353389
[No Abstract] [Full Text] [Related]
25. Tailor-made chemotherapy for non-small cell lung cancer patients.
Huang CL; Yokomise H; Fukushima M; Kinoshita M
Future Oncol; 2006 Apr; 2(2):289-99. PubMed ID: 16563096
[TBL] [Abstract][Full Text] [Related]
26. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.
Oxnard GR
Arch Pathol Lab Med; 2012 Oct; 136(10):1205-9. PubMed ID: 23020725
[TBL] [Abstract][Full Text] [Related]
27. CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.
Pan M; Santamaria M; Wollman DB
Nat Clin Pract Oncol; 2007 Oct; 4(10):603-7. PubMed ID: 17898810
[TBL] [Abstract][Full Text] [Related]
28. Targeted treatment tested as potential cancer cure.
Hayden EC
Nature; 2011 Nov; 479(7373):281. PubMed ID: 22094668
[No Abstract] [Full Text] [Related]
29. Medicine. Why a new cancer drug works well, in some patients.
Marx J
Science; 2004 Apr; 304(5671):658-9. PubMed ID: 15118127
[No Abstract] [Full Text] [Related]
30. INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.
Govindan R
J Clin Oncol; 2010 Feb; 28(5):713-5. PubMed ID: 20038722
[No Abstract] [Full Text] [Related]
31. Targeting resistance in lung cancer.
Cancer Discov; 2013 Dec; 3(12):OF9. PubMed ID: 24327718
[No Abstract] [Full Text] [Related]
32. Two cases of non-small-cell lung cancer with rare complex mutation of EGFR exon 18 but different response to targeted therapy.
Gauthier H; Douchet G; Lehmann-Che J; Meignin V; Raynaud C; Sabatier P; de Cremoux H; Poirot B; Culine S; Pouessel D; de Cremoux P
J Thorac Oncol; 2014 Oct; 9(10):e78-9. PubMed ID: 25521408
[No Abstract] [Full Text] [Related]
33. Update on systemic therapy of advanced non-small-cell lung cancer.
Cufer T; Knez L
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1189-203. PubMed ID: 25098682
[TBL] [Abstract][Full Text] [Related]
34. Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation.
van Noesel J; van der Ven WH; van Os TA; Kunst PW; Weegenaar J; Reinten RJ; Kancha RK; Duyster J; van Noesel CJ
J Clin Oncol; 2013 Apr; 31(10):e161-4. PubMed ID: 23358982
[No Abstract] [Full Text] [Related]
35. Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.
Neal JW; Sequist LV
J Clin Oncol; 2012 Jun; 30(18):2280-2. PubMed ID: 22508823
[No Abstract] [Full Text] [Related]
36. [Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
Shi YK
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):398-400. PubMed ID: 22883466
[No Abstract] [Full Text] [Related]
37. Targeted therapy in lung cancer: survival, quality of life improved for some patients.
Printz C
Cancer; 2014 Sep; 120(17):2625-6. PubMed ID: 25142921
[No Abstract] [Full Text] [Related]
38. EGFR TKIs for advanced NSCLC: practical questions.
Perez-Soler R
Oncology (Williston Park); 2010 Apr; 24(5):400-1, 409. PubMed ID: 20480737
[No Abstract] [Full Text] [Related]
39. [Side effects of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)].
Takeda K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():245-9. PubMed ID: 25831761
[No Abstract] [Full Text] [Related]
40. The cellular origins of drug resistance in cancer.
Oxnard GR
Nat Med; 2016 Mar; 22(3):232-4. PubMed ID: 26937615
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
